Impact of enzyme replacement therapy and hematopoietic stem cell therapy on growth in patients with Hunter syndrome

Molecular Genetics and Metabolism Reports

Volumn 1, Issue 1, 2014, Pages 184-196

  Patel, Pravin ^a   Suzuki, Yasuyuki ^b   Tanaka, Akemi ^c   Yabe, Hiromasa ^d   Kato, Shunichi ^d   Shimada, Tsutomu ^a   Mason, Robert W ^a   Orii, Kenji E ^e   Fukao, Toshiyuki ^b   Orii, Tadao ^b   Tomatsu, Shunji ^a,b  

^a NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

^b GIFU UNIVERSITY   (Japan)

^c OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d TOKAI UNIVERSITY   (Japan)

^e GIFU UNIVERSITY HOSPITAL   (Japan)

Author keywords

Enzyme replacement therapy; Growth impact; Height; Hematopoietic stem cell therapy; Hunter syndrome

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME REPLACEMENT; GROWTH CURVE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUNTER SYNDROME; INFANT; JAPANESE (PEOPLE); MALE; PRESCHOOL CHILD; SCHOOL CHILD; THERAPY EFFECT; BODY GROWTH; CLINICAL TRIAL;

EID: 84905161961     PISSN: None     EISSN: 22144269     Source Type: Journal    
DOI: 10.1016/j.ymgmr.2014.04.001     Document Type: Article

References (32)

1. M. Scarpa Mucopolysaccharidosis type II [updated 2011 Feb 22] R.A. Pagon, M.P. Adam, T.D. Bird, C.R. Dolan, C.T. Fong, K. Stephens, GeneReviews™ [Internet] 2007 Nov 06 University of Washington, Seattle Seattle (WA) 1993 2013
2. V. Valayannopoulos Enzyme replacement therapy and substrate reduction therapy in lysosomal storage disorders with neurological expression Handb. Clin. Neurol. 113 2013 1851 1857
3. J. Nelson, J. Crowhurst, B. Carey, and L. Greed Incidence of the mucopolysaccharidoses in Western Australia Am. J. Med. Genet. A 123A 2003 310 313 (Pubitemid 37464354)
4. F. Baehner, C. Schmiroeskamp, F. Krummenauer, E. Miebach, M. Bajbouj, C. Whybra, A. Kohlschutter, C. Kampmann, and M. Beck Cumulative incidence rates of the mucopolysaccharidoses in Germany J. Inherit. Metab. Dis. 28 2005 1011 1017 (Pubitemid 43168938)
5. H.Y. Lin, S.P. Lin, C.K. Chuang, D.M. Niu, M.R. Chen, F.J. Tsai, M.C. Chao, P.C. Chiu, S.J. Lin, L.P. Tsai, W.L. Hwu, and J.L. Lin Incidence of the mucopolysaccharidoses in Taiwan, 1984-2004 Am. J. Med. Genet. A 149A 2009 960 964
6. J.E. Wraith, M. Beck, R. Giugliani, J. Clarke, R. Martin, J. Muenzer HOS Investigators Initial report from the Hunter Outcome Survey Genet. Med. 10 2008 508 516
7. E.M.K. da Silva, M.L.W. Strufaldi, R.B. Andriolo, and L.A. Silva Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome) Cochrane Database Syst. Rev. Issue 11 2011 10.1002/14651858.CD008185. pub2 (Art. No.: CD008185)
8. J.E. Wraith, M. Scarpa, M. Beck, O.A. Bodamer, L. De Meirleir, N. Guffon, A. Meldgaard Lund, G. Malm, A.T. Van der Ploeg, and J. Zeman Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy Eur. J. Pediatr. 167 3 2008 Mar 267 277
9. T. Ochiai, Y. Suzuki, T. Kato, H. Shichino, M. Chin, H. Mugishima, and T. Orii Natural history of extensive Mongolian spots in mucopolysaccharidosis type II (Hunter syndrome): a survey among 52 Japanese patients J. Eur. Acad. Dermatol. Venereol. 8 2007 1082 1085 (Pubitemid 47304610)
10. N.J. Mendelsohn, P. Harmatz, O. Bodamer, B.K. Burton, R. Giugliani, S.A. Jones, C. Lampe, G. Malm, R.D. Steiner, and R. Parini Hunter Outcome Survey Investigators. Importance of surgical history in diagnosing mucopolysaccharidosis type II (Hunter syndrome): data from the Hunter Outcome Survey Genet Med. 12 2010 816 822
11. S.A. Jones, R. Parini, P. Harmatz, R. Giugliani, J. Fang, N.J. Mendelsohn HOS Natural History Working Group on behalf of HOS Investigators The effect of idursulfase on growth in patients with Hunter syndrome: data from the Hunter Outcome Survey (HOS) Mol. Genet. Metab. 109 2013 41 48
12. J. Muenzer, J.E. Wraith, M. Beck, R. Giugliani, P. Harmatz, C.M. Eng, A. Vellodi, R. Martin, U. Ramaswami, M. Gucsavas-Calikoglu, S. Vijayaraghavan, S. Wendt, A.C. Puga, B. Ulbrich, M. Shinawi, M. Cleary, D. Piper, A.M. Conway, and A. Kimura A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome) Genet. Med. 8 2006 465 473
13. J. Muenzer, M. Beck, C.M. Eng, R. Giugliani, P. Harmatz, R. Martin, U. Ramaswami, A. Vellodi, J.E. Wraith, M. Cleary, M. Gucsavas-Calikoglu, A.C. Puga, M. Shinawi, B. Ulbrich, S. Vijayaraghavan, S. Wendt, A.M. Conway, A. Rossi, D.A. Whiteman, and A. Kimura Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome Genet. Med. 13 2011 95 101
14. J. Muenzer, M. Beck, R. Giugliani, Y. Suzuki, A. Tylki-Szymanska, V. Valayannopoulos, A. Vellodi, and J.E. Wraith Idursulfase treatment of Hunter syndrome in children younger than 6 years: results from the Hunter Outcome Survey Genet. Med. 13 2011 102 109
15. B.A. Heese Current strategies in the management of lysosomal storage diseases Semin. Pediatr. Neurol. 15 2008 119 126
16. M. Beck Mucopolysaccharidosis Type II (Hunter Syndrome): clinical picture and treatment Curr. Pharm. Biotechnol. 12 2011 861 866
17. G. Schulze-Frenking, S.A. Jones, J. Roberts, M. Beck, and J.E. Wraith Effects of enzyme replacement therapy on growth in patients with mucopolysaccharidosis type II J. Inherit. Metab. Dis. 34 2011 203 208
18. A. Tanaka, T. Okuyama, Y. Suzuki, N. Sakai, H. Takakura, T. Sawada, T. Tanaka, T. Otomo, T. Ohashi, M. Ishige-Wada, H. Yabe, T. Ohura, N. Suzuki, K. Kato, S. Adachi, R. Kobayashi, H. Mugishima, and S. Kato Long-term efficacy of hematopoietic stem cell transplantation on brain involvement in patients with mucopolysaccharidosis type II: a nationwide survey in Japan Mol. Genet. Metab. 107 2012 513 520
19. P. Patel, Y. Suzuki, M. Maeda, E. Yasuda, T. Shimada, K.E. Orii, T. Orii, and S. Tomatsu Growth charts for patients with Hunter Syndrome Mol. Genet. Metab. Rep. 1 2014 5 18
20. Y.B. Sohn, S.Y. Cho, S.W. Park, S.J. Kim, A.R. Ko, E.K. Kwon, S.J. Han, and D.K. Jin Phase I/II clinical trial of enzyme replacement therapy with idursulfase beta in patients with mucopolysaccharidosis II (Hunter syndrome) Orphanet J. Rare Dis. 8 2013 42
21. P. Harmatz, R. Giugliani, I.V. Schwartz, N. Guffon, E.L. Teles, M.C. Miranda, J.E. Wraith, M. Beck, L. Arash, M. Scarpa, D. Ketteridge, J.J. Hopwood, B. Plecko, R. Steiner, C.B. Whitley, P. Kaplan, Z.F. Yu, S.J. Swiedler, C. Decker MPS VI Study Group Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase Mol Genet Metab. 94 2008 469 475
22. T. Okuyama, A. Tanaka, Y. Suzuki, H. Ida, T. Tanaka, G.F. Cox, Y. Eto, and T. Orii Japan Elaprase Treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (Mucopolysaccharidosis II, MPS II) Mol. Genet. Metab. 99 2010 18 25
23. K. Akiyama, Y. Shimada, T. Higuchi, M. Ohtsu, H. Nakauchi, H. Kobayashi, T. Fukuda, H. Ida, Y. Eto, B.E. Crawford, J.R. Brown, and T. Ohashi Enzyme augmentation therapy enhances the therapeutic efficacy of bone marrow transplantation in mucopolysaccharidosis type II mice Mol. Genet. Metab. 13 2013 00325 00329
24. Y. Yamada, K. Kato, K. Sukegawa, S. Tomatsu, S. Fukuda, S. Emura, S. Kojima, T. Matsuyama, W.S. Sly, N. Kondo, and T. Orii Treatment of MPS VII (Sly disease) by allogeneic BMT in a female with homozygous A619V mutation Bone Marrow Transplant. 21 1998 629 634 (Pubitemid 28138265)
25. Y. Chinen, T. Higa, S. Tomatsu, Y. Suzuki, T. Orii, and N. Hyakuna Long-term therapeutic efficacy of allogenic bone marrow transplantation in a patient with mucopolysaccharidosis IVA Mol. Genet. Metab. Rep. 1 2014 31 41
26. J.J. Boelens, V. Rocha, M. Aldenhoven, R. Wynn, A. O'Meara, G. Michel, I. Ionescu, S. Parikh, V.K. Prasad, P. Szabolcs, M. Escolar, E. Gluckman, M. Cavazzana-Calvo, and J. Kurtzberg EUROCORD, Inborn error Working Party of EBMT and Duke University. Risk factor analysis of outcomes after unrelated cord blood transplantation in patients with hurler syndrome Biol. Blood Marrow Transplant. 15 2009 618 625
27. V.K. Prasad, and J. Kurtzberg Transplant outcomes in mucopolysaccharidoses Semin. Hematol. 47 2010 59 69
28. S. Tomatsu, T. Fujii, M. Fukushi, T. Oguma, T. Shimada, M. Maeda, K. Kida, Y. Shibata, H. Futatsumori, A.M. Montaño, R.W. Mason, S. Yamaguchi, Y. Suzuki, and T. Orii Newborn screening and diagnosis of mucopolysaccharidoses Mol. Genet. Metab. 110 2013 42 53
29. B.J. Wolfe, S. Blanchard, M. Sadilek, C.R. Scott, F. Turecek, and M.H. Gelb Tandem mass spectrometry for the direct assay of lysosomal enzymes in dried blood spots: application to screening newborns for mucopolysaccharidosis II (Hunter Syndrome) Anal. Chem. 83 2011 1152 1156
30. M. Fuller, J.N. Tucker, D.J. Lang, C.J. Dean, M.J. Fietz, P.J. Meikle, and J.J. Hopwood Screening patients referred to a metabolic clinic for lysosomal storage disorders J. Med. Genet. 48 2011 422 425
31. P.J. Meikle, D.J. Grasby, C.J. Dean, D.L. Lang, M. Bockmann, A.M. Whittle, M.J. Fietz, H. Simonsen, M. Fuller, D.A. Brooks, and J.J. Hopwood Newborn screening for lysosomal storage disorders Mol. Genet. Metab. 88 2006 307 314 (Pubitemid 44107765)
32. C.R. Scott, S. Elliott, N. Buroker, L.I. Thomas, J. Keutzer, M. Glass, M.H. Gelb, and F. Turecek Identification of infants at risk for developing Fabry, Pompe, or mucopolysaccharidosis-I from newborn blood spots by tandem mass spectrometry J. Pediatr. 163 2013 498 503